Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

The U.S. Food and Drug Administration approved changing the prescribing information for Eli Lilly's Alzheimer's drug Kisunla to allow more gradual dosing to lower the risk of a potentially dangerous ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

By Fraiser Kansteiner Jun 26, 2025 8:50am Eli Lilly North Carolina sterile injectables auto-injector ...

The global fight between Eli Lilly and Novo Nordisk for dominance in the red-hot weight-loss drug market is shifting to India, one of the fastest-growing pharmaceutical frontiers. As rising ...

Study Overview: Eli Lilly and Company is conducting a Phase 3 study titled ‘ACCLAIM-Lp (a)’ to evaluate the efficacy of Lepodisiran in reducing major adverse cardiovascular events in adults ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge announces a $300 million funding round.

Eli Lilly is now running additional studies of the drug in combination with its own weight loss injection, Zepbound, Ken Custer, president of Lilly Cardiometabolic Health, told CNBC.

Eli Lilly is now running additional studies of the drug in combination with its own weight loss injection, Zepbound, Ken Custer, president of Lilly Cardiometabolic Health, told CNBC.